HS-10370 / Jiangsu Hansoh Pharma - LARVOL DELTA

A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=762 | Not yet recruiting | Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.

New P1 trial • Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Safety and efficacy of HS-10370 in KRAS G12C-mutated advanced solid tumors: Updated results from phase 1 study (AACR 2025) - P1/2 | "With extended follow-up, HS-10370 continued to demonstrate impressive and durable antitumor activity and was well tolerated in patients with advanced KRAS G12C-positive solid tumor."

Clinical • Metastases • P1 data • Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • KRAS

A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=350 | Not yet recruiting | Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.

Metastases • New P1 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Safety and efficacy of HS-10370 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC) (AACR 2024) - P1/2 | "HS-10370 was well tolerated and showed inspiring antitumor activities in KRAS G12C mutated advanced solid tumors, especially in NSCLC."

Clinical • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • KRAS

Phase 1/2 Study of HS-10370 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=176 | Recruiting | Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Monotherapy • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • KRAS

Phase 1/2 Study of HS-10370 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=176 | Not yet recruiting | Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.

Monotherapy • New P1/2 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • KRAS